{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-25-000009","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.150342+00:00","generated_at":"2026-05-26T01:51:25.343564+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aurinia Q4 2024 net income $1.4M on 33% revenue growth, LUPKYNIS sales up 36% YoY","bullets":["Q4 total revenue $59.9M (+33% YoY); net product sales $57.6M (+36%); license revenue $2.3M (-18%).","Q4 net income $1.4M vs $(26.9)M loss; full year net income $5.8M vs $(78.0)M loss.","Cash flow from operations Q4 $30.1M (+110% YoY); full year $44.4M vs $(33.5)M.","2025 guidance: total revenue $250-260M, net product sales $240-250M; AUR200 Phase 1 data expected Q2 2025.","Cash $358.5M at Dec 31, 2024; repurchased 6.1M shares for $41M in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-25-000009","json":"https://secwatch.observer/filing/0001600620-25-000009.json","markdown":"https://secwatch.observer/filing/0001600620-25-000009.md","text":"https://secwatch.observer/filing/0001600620-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000009/0001600620-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000009/auph-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:51:25.343564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}